17,261 trials
Hip Fracture · Myocardial Ischemia · Inflammation
Primary: Percentage of All Enrolled Patients With a Peri-operative Rise in High-sensitivity Cardiac Troponin I — 20 percentage of patients
Tularemia
Primary: Safety: Adverse Event Category Rates for All Vaccinations — 264; 162; 53; 48 Adverse events
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
Breast Cancer
Primary: Change in Lumbar Density From Baseline to 12 Months — -0.036; -0.021 g/cm^2 — p=0.15
HIV-1 Infection
Primary: Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO — 8; 4 Participants
Non-melanoma Skin Cancer
Primary: The Primary Efficacy Measure Was the Investigator's Global Assessment of Healing (IGAH). — 2.75; 2.25; 3.00; 3.00 units on a scale — p=0.263
Crohn's Disease
Primary: Evaluate the Effects of TSO on the Induction of Response in Crohn's Disease, as Measured Primarily by Crohn's Disease Activity Index (CDAI) — 55; 58 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumor Response Rate — 1 Participants
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Ability to Successfully Deliver the Investigational Therapy Without Incurring the Protocol Suspension Rules — 51 Participants
Leukemia · Acute Disease · Acute Myeloid Leukemia
Primary: Remission Rate Defined as the Percentage of Patients Whose Respnse is CR or CRp Based on International Working Group (IWG) Response Criteria and Treatment Outcomes…
Seasonal Allergic Rhinitis
Primary: Change in rTNSS From Baseline to End of Treatment — 10.3; 10.4; 10.4; 10.3 units on a scale — p=<0.0001
Pain · Hypogonadism
Primary: Brief Pain Inventory (BPI) at Week 14 — 10.2; 9.7; 5.3; 5.1 units on a scale
Neurobehavioral Manifestations · Drug Related Sleep Disturbance · Alcohol Intoxication
Primary: Lane Position Deviation — -1.25; -1.36; -1.22; -1.21 feet
Male Breast Cancer · Recurrent Breast Cancer · Skin Metastases
Primary: Anti-tumor Effects of Imiquimod as Assessed by Modified World Health Organization (WHO) Criteria — 14; 5; 5; 3 Participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Incidence of Acute Graft-versus-host Disease (GVHD) — 44.7 percentage of participants